Gonadorelin vs HCG on TRT: Which Is Better for Fertility Preservation?

Why This Is One of the Most Important Decisions on TRT

If you are on testosterone replacement therapy — or seriously considering it — fertility preservation is not optional. It is a decision you need to make before your first dose. Exogenous testosterone shuts down sperm production in most men within three to four months. If you want children now or in the future, you need a plan.

For decades, that plan was straightforward: add HCG (human chorionic gonadotropin) to your TRT protocol. HCG mimics luteinizing hormone and keeps the testes functioning while external testosterone does the heavy lifting. It worked. It had decades of clinical data behind it.

Then, in March 2020, the FDA reclassified HCG from a drug to a biologic under the Biologics Price Competition and Innovation Act (BPCIA). This moved HCG from the standard 505(b) drug compounding pathway to the much more restrictive 351 biologics pathway. The practical result: the majority of compounding pharmacies that had been producing affordable HCG for TRT clinics were no longer permitted to do so. Supply collapsed. Costs for brand-name HCG (Pregnyl, Novarel) climbed significantly.

Clinics needed an alternative. Gonadorelin — a synthetic version of the body's own gonadotropin-releasing hormone (GnRH) — became that alternative almost overnight. Today, most telehealth TRT providers prescribe gonadorelin instead of HCG by default. But here is the problem: the clinical evidence behind that switch is far thinner than most patients realize.

This guide lays out exactly what each drug does, what the research actually supports, where the evidence gaps are, and how to decide which one belongs in your protocol.

How TRT Shuts Down Fertility

Understanding why you need either of these medications requires understanding the HPG (hypothalamic-pituitary-gonadal) axis — the hormonal feedback loop that controls testosterone production and sperm output.

Under normal conditions, the process works like this:

1. Your hypothalamus releases GnRH (gonadotropin-releasing hormone) in pulses roughly every 60 to 120 minutes.
2. GnRH signals your pituitary gland to release two hormones: LH (luteinizing hormone) and FSH (follicle-stimulating hormone).
3. LH tells the Leydig cells in your testes to produce testosterone.
4. FSH acts on the Sertoli cells to support spermatogenesis — the production of mature sperm.
5. When testosterone levels are sufficient, the hypothalamus detects this and reduces GnRH output. This is negative feedback.

When you introduce exogenous testosterone through TRT, your brain detects the high testosterone levels and shuts down the entire upstream cascade. GnRH output drops. LH and FSH plummet. Without LH, intratesticular testosterone — which needs to be 50 to 100 times higher than blood levels for sperm production — crashes. Without FSH, the Sertoli cells lose the signal to support spermatogenesis.

The result: testicular atrophy (your testes physically shrink) and severely reduced or absent sperm production. A 2005 study by Coviello et al. found that 200 mg/week of testosterone enanthate alone reduced intratesticular testosterone by approximately 94%. This is not a side effect of bad TRT — it is the expected physiological response to exogenous testosterone in every man.

HCG: The Gold Standard (With Caveats)

HCG (human chorionic gonadotropin) is a hormone naturally produced during pregnancy. When administered to men, it acts as a direct LH analog — it binds to the same LH receptors on the Leydig cells in the testes and stimulates testosterone production and, indirectly, spermatogenesis.

How HCG Works on TRT

HCG bypasses the hypothalamus and pituitary entirely. It goes straight to the testes and tells them to keep working, even though your brain has shut down its own LH production. This is its greatest strength and its greatest limitation.

Strength: Because HCG acts directly at the testicular level, its effect does not depend on a functioning pituitary gland. If your HPG axis is fully suppressed by TRT (which it will be), HCG still works. It does not need the upstream machinery to be operational.

Limitation: HCG primarily stimulates LH receptors. It does not significantly raise FSH levels. FSH is the hormone that directly supports spermatogenesis through the Sertoli cells. While maintaining intratesticular testosterone via HCG does support some sperm production, it is not providing the full FSH signal that the testes normally receive.

What the Evidence Shows

HCG has the strongest evidence base of any fertility-preserving TRT adjunct:

• Coviello et al., 2005 (PMID 15713727): 250 IU of HCG every other day largely prevented the intratesticular testosterone crash caused by 200 mg/week testosterone enanthate. This is the foundational study demonstrating that low-dose HCG can maintain testicular function alongside TRT.
• Hsieh et al., 2013: Men receiving concurrent low-dose HCG (500 IU three times per week) with TRT maintained spermatogenesis in most cases, compared to TRT-only controls who developed oligospermia or azoospermia.
• Retrospective cohort data: Multiple retrospective analyses from men's health clinics confirm that HCG co-therapy at doses of 500 to 1,500 IU two to three times per week reduces the incidence of testicular atrophy and maintains measurable sperm counts in the majority of men on TRT.

Standard HCG Dosing on TRT

Goal	Typical Dose	Frequency	Route
Testicular maintenance	250–500 IU	Every other day or 3×/week	Subcutaneous
Fertility preservation	500–1,000 IU	2–3×/week	Subcutaneous
Active conception attempt	1,000–1,500 IU	3×/week (often with FSH)	Subcutaneous or IM

HCG Side Effects

The main side effect of HCG relevant to men on TRT is elevated estradiol. HCG stimulates the Leydig cells to produce testosterone locally, and those cells contain aromatase, the enzyme that converts testosterone to estrogen. Men who already aromatize heavily — typically those with higher body fat — may see estradiol levels climb on HCG, sometimes requiring an aromatase inhibitor adjustment or dose reduction.

Other potential side effects include water retention, mood changes related to estradiol fluctuations, and (rarely) gynecomastia. These are dose-dependent and manageable with proper estradiol monitoring.

Availability and Cost in 2026

After the 2020 FDA reclassification, compounded HCG availability dropped sharply. As of 2026, the situation has partially stabilized:

• 503B outsourcing pharmacies can still compound HCG, but only a small fraction do — a 2023 study found only 5 of 75 responding 503B pharmacies were producing it.
• Brand-name HCG (Pregnyl, Novarel) remains available by prescription but costs $150 to $300+ per month depending on dose and pharmacy.
• Compounded HCG from pharmacies that still offer it runs roughly $50 to $100 per month.
• Some clinics have shifted to recombinant HCG (choriogonadotropin alfa), but availability and cost vary.

Gonadorelin: The Upstream Alternative

Gonadorelin is a synthetic version of GnRH — the exact same 10-amino-acid peptide your hypothalamus naturally produces. Instead of acting directly at the testes like HCG, gonadorelin works at the pituitary level. It binds to GnRH receptors and stimulates the pituitary to release its own LH and FSH.

In theory, this is more physiological than HCG because it preserves the natural signaling cascade. In practice, the pharmacology creates significant challenges that are not always discussed.

How Gonadorelin Works on TRT

When you inject gonadorelin subcutaneously, it triggers a pulse of LH and FSH release from your pituitary — assuming the pituitary is still responsive. This LH then travels to the testes and stimulates testosterone production and testicular function, similar to HCG's downstream effect. The FSH simultaneously supports spermatogenesis through the Sertoli cells.

This sounds ideal. The problem is the pharmacokinetics.

The Half-Life Problem

Gonadorelin has an intravenous plasma half-life of approximately 2 to 4 minutes (Handelsman and Swerdloff, 1986). Even with subcutaneous injection — which slows absorption and extends the effective window somewhat — the molecule is cleared rapidly. Compare this to HCG, which has a half-life of 24 to 36 hours.

This matters enormously. The clinical studies that demonstrated gonadorelin's effectiveness for fertility restoration used pulsatile GnRH pump therapy — a device worn continuously that delivers small doses (5 to 20 mcg) every 60 to 120 minutes around the clock, mimicking the body's natural pulsatile GnRH release pattern.

The twice-weekly or three-times-weekly subcutaneous injections prescribed by most TRT clinics today are not what those studies tested. No published randomized controlled trial has compared the standard telehealth clinic protocol (100 mcg subcutaneous two to three times per week) to HCG in men on suppressive TRT doses.

Standard Gonadorelin Dosing on TRT

Goal	Typical Dose	Frequency	Route	Evidence Level
Testicular maintenance	100 mcg	2–3×/week	Subcutaneous	Low (clinical consensus)
Enhanced preservation	100–200 mcg	Daily or 2×/day	Subcutaneous	Very low (anecdotal)
Fertility restoration (pump)	5–20 mcg	Every 60–120 min	Pump infusion	Moderate (RCT data)

The most common protocol prescribed at U.S. telehealth TRT clinics is 100 mcg subcutaneously two to three times per week. This is based on clinical practice consensus and GnRH receptor physiology — not on a published phase III trial for this specific use case. The evidence quality for this specific application is low.

Gonadorelin Side Effects

Gonadorelin generally produces fewer estrogen-related side effects than HCG. Because it works upstream rather than directly stimulating Leydig cell testosterone production, the intratesticular testosterone spike — and the associated aromatization — tends to be smaller. Men who struggle with elevated estradiol on HCG may find gonadorelin more tolerable from a hormonal balance perspective.

The primary downside is the dosing frequency. For men already managing their TRT protocol, adding daily subcutaneous injections is a meaningful compliance burden. Some providers prescribe twice-weekly dosing for convenience, but this further deviates from the pulsatile delivery that the evidence actually supports.

Cost in 2026

Gonadorelin is widely available from compounding pharmacies since it was not affected by the 2020 biologic reclassification. Cost typically ranges from $30 to $80 per month, making it generally cheaper than HCG. This accessibility and lower cost are significant reasons why telehealth clinics adopted it so quickly.

Head-to-Head Comparison

Here is the honest side-by-side. Pay attention to the evidence quality column — it tells you how confident you should be in each claim.

Factor	HCG	Gonadorelin
Mechanism	Direct LH analog — acts on testicular Leydig cells	GnRH agonist — stimulates pituitary to release LH + FSH
FSH stimulation	Minimal — does not significantly raise FSH	Yes — stimulates both LH and FSH release
Half-life	24–36 hours	2–10 minutes (IV); slightly longer SQ
Dosing frequency	2–3× per week	2–3× per week (clinic standard) or daily
Evidence for fertility on TRT	Moderate to strong (multiple studies)	Low (no RCT for standard SQ protocol)
Evidence for testicular maintenance	Strong	Low to moderate (clinical practice reports)
Estrogen impact	Raises estradiol (Leydig cell aromatization)	Lower estrogen effect vs equivalent HCG
Depends on pituitary function	No — bypasses pituitary entirely	Yes — requires functional pituitary GnRH receptors
Availability (US, 2026)	Limited — few compounders; brand-name available	Widely available from compounding pharmacies
Monthly cost	$50–$300+	$30–$80

Who Should Choose Which

There is no single right answer. The best choice depends on your specific situation, goals, and what your clinic can access. Here is a decision framework:

HCG Is Likely the Better Choice If:

• Active fertility is your priority. You are trying to conceive now or within the next 6 to 12 months. HCG has significantly more clinical data supporting its ability to maintain spermatogenesis during TRT.
• You have been on TRT for years. Long-term HPG suppression may reduce pituitary responsiveness to GnRH, making gonadorelin less effective. HCG's direct testicular action is independent of pituitary function.
• You can access it. If your clinic or pharmacy can source compounded or brand-name HCG at a reasonable cost, the evidence advantage makes it the stronger option for fertility.
• You tolerate the estradiol increase. If your aromatization is manageable and estradiol stays within range, the estrogen side effect is not a dealbreaker.

Gonadorelin Is Likely the Better Choice If:

• Fertility is a future concern, not an immediate one. You want to maintain testicular size and keep the option open, but you are not actively trying to conceive. Gonadorelin provides some protective effect at lower evidence certainty, which may be sufficient for a maintenance goal.
• You aromatize heavily. If HCG spikes your estradiol to problematic levels despite dose adjustments, gonadorelin's lower estrogen impact is a practical advantage.
• HCG is inaccessible or cost-prohibitive. If your pharmacy cannot source HCG or the cost is unsustainable, gonadorelin is a reasonable alternative — better than no adjunct at all.
• You are early in your TRT journey. If you have recently started TRT and your pituitary is still relatively responsive, gonadorelin may produce a more robust response than it would after years of suppression.

Consider Both Together If:

Some progressive men's health clinics use combination protocols — lower doses of both HCG and gonadorelin — to cover both the pituitary and testicular levels simultaneously. This approach is not well-studied, but the physiological rationale is sound: HCG maintains direct testicular stimulation while gonadorelin keeps the pituitary from fully shutting down. If your provider is experienced with combination protocols and you have active fertility goals, this is worth discussing.

What About Enclomiphene?

If fertility preservation is your primary concern, there is a third option that takes a completely different approach: enclomiphene.

Enclomiphene is the active isomer of clomiphene citrate (Clomid). It is a selective estrogen receptor modulator (SERM) that blocks estrogen feedback at the pituitary, causing your body to increase its own LH and FSH production. Unlike TRT, enclomiphene does not suppress the HPG axis — it stimulates it. This means your body continues producing testosterone endogenously and sperm production is maintained or even improved.

The tradeoff: enclomiphene typically raises testosterone by 100 to 200 ng/dL. For men with mildly low testosterone (say, 250 to 350 ng/dL), this may be enough. For men who need to reach 600 to 900 ng/dL, enclomiphene alone usually will not get there. It is also not a direct substitute for TRT — it is an alternative with a different ceiling. (For a deeper comparison, see our guide on TRT vs Clomid.)

Monitoring on Either Protocol

Regardless of whether you add HCG or gonadorelin to your TRT, you need regular blood work to verify the protocol is working. The standard fertility-preservation monitoring panel includes:

Marker	Why It Matters	Frequency
Total testosterone	Confirm TRT is working as intended	Every 60–90 days
Free testosterone	Bioavailable testosterone — what actually reaches tissues	Every 60–90 days
Estradiol (E2)	Especially important on HCG — detects excess aromatization	Every 60–90 days
LH	Should be suppressed on TRT; on gonadorelin, a measurable LH confirms pituitary response	Every 90 days
FSH	Critical for spermatogenesis — if FSH is undetectable, sperm production is likely compromised	Every 90 days
Semen analysis	The definitive test — counts, motility, and morphology	Every 3–6 months if fertility is a goal
Hematocrit	TRT raises red blood cell production — monitor for polycythemia	Every 60–90 days

One crucial point: if you are on gonadorelin and your LH remains undetectable on blood work, your pituitary is not responding to the medication. This means gonadorelin is not providing the testicular stimulation you are counting on. In this scenario, switching to HCG — which does not require pituitary function — is the appropriate clinical decision. This is exactly the kind of finding that regular blood work monitoring catches.

The Bottom Line

HCG and gonadorelin both aim to solve the same problem — preserving testicular function and fertility while on TRT — but they are not equivalent.

HCG has the stronger evidence base. Multiple studies demonstrate its ability to maintain intratesticular testosterone and spermatogenesis during TRT. It works regardless of pituitary function. Its main drawbacks are reduced availability since 2020, higher cost, and the potential to raise estradiol.

Gonadorelin has a physiological advantage in that it stimulates both LH and FSH through the natural signaling cascade. But the standard clinic dosing protocol (100 mcg subcutaneous two to three times per week) has not been validated in a randomized controlled trial for men on suppressive TRT. Its effectiveness depends on pituitary responsiveness, which may be blunted in long-term TRT users.

Neither is a magic bullet. Both require monitoring to confirm they are doing what you need them to do. And both are far better than the alternative — being on TRT with no fertility preservation strategy at all.

The best approach is the one designed around your specific goals, timeline, and lab results. If you are starting TRT or reconsidering your current protocol, this is a conversation to have with a provider who understands the evidence behind both options — not just the one their pharmacy happens to stock.

Key Takeaways

• TRT suppresses sperm production within 3 to 4 months by shutting down LH and FSH. Recovery is possible but not guaranteed, especially after long-term use.
• HCG is the gold standard for fertility preservation on TRT. It acts directly at the testes, has moderate-to-strong clinical evidence, and does not depend on pituitary function.
• Gonadorelin works upstream by stimulating the pituitary to release LH and FSH. It has theoretical advantages (FSH stimulation, lower estradiol) but the common clinic dosing protocol lacks randomized trial data.
• The 2020 FDA reclassification moved HCG to the biologics pathway, dramatically reducing compounding availability and driving the shift to gonadorelin.
• Gonadorelin requires a responsive pituitary — if LH remains undetectable on blood work, the medication is not working and a switch to HCG is warranted.
• Cost favors gonadorelin ($30 to $80/month vs $50 to $300+ for HCG), but cost should not be the primary factor in a fertility decision.
• Enclomiphene is a third path — it preserves fertility without TRT but produces lower testosterone gains.
• Regular blood work is non-negotiable on either protocol. LH, FSH, estradiol, and periodic semen analysis are essential to verify your plan is working.